title: Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?
abstract: Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction (STEMI). First generation drug-eluting stents (DES), (sirolimus drug-eluting stents and paclitaxel drug-eluting stents), reduce the risk of restenosis and target vessel revascularization compared to bare metal stents. However, stent thrombosis emerged as a major safety concern with first generation DES. In response to these safety issues, second generation DES were developed with different drugs, improved stent platforms and more biocompatible durable or bioabsorbable polymeric coating. This article presents an overview of safety and efficacy of the first and second generation DES in STEMI.
authors.affiliation: Shuji Otsuki, Manel Sabaté, Thorax Institute, Department of Cardiology, Hospital Clinic, University of Barcelona, 08015 Barcelona, Spain.
authors.forename: Shuji
authors.initials: S
authors.lastname: Otsuki
authors.affiliation: Shuji Otsuki, Manel Sabaté, Thorax Institute, Department of Cardiology, Hospital Clinic, University of Barcelona, 08015 Barcelona, Spain.
authors.forename: Manel
authors.initials: M
authors.lastname: Sabaté
keywords: Bioresorbable vascular scaffold; Drug-eluting stents; Paclitaxel drug-eluting stents; ST-segment elevation myocardial infarction; Sirolimus drug-eluting; Stent thrombosis; Zotarolimus-eluting stents